Treatment of a complex orthopaedic infection due to extensively drug-resistant Pseudomonas aeruginosa

BMJ Case Reports
Sidra HassanPriya Nori

Abstract

According to the Centers for Disease Control and Prevention (CDC), approximately 51 000 healthcare-associated infections caused by Pseudomonas aeruginosa occur annually in the USA, more than 6000 of which (13%) are caused by multidrug resistant (MDR) strains. Ceftolozane/tazobactam (TOL/TAZ) (Zerbaxa) was approved by the US Food and Drug Administration (FDA) in December 2014 for the treatment of complicated intra-abdominal and urinary tract infections. At this time, clinical data on the role of TOL/TAZ treatment outside of FDA-approved indications is limited. Herein, we present a case of extensively drug-resistant (XDR) P. aeruginosa osteomyelitis of the upper extremity, which was successfully treated with TOL/TAZ for 8 weeks with optimal clinical and laboratory responses. Monotherapy with TOL/TAZ appears effective for treatment of complicated bone and joint infections with XDR P. aeruginosa in combination with comprehensive surgical management, particularly when few antibiotic options exist.

References

Dec 27, 2005·Antimicrobial Agents and Chemotherapy·Valerie AloushYehuda Carmeli
Mar 17, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Daniel J Diekema, Michael B Edmond
Jul 24, 2007·International Journal of Antimicrobial Agents·Shinobu TakedaKeizo Yamaguchi
Jul 29, 2011·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A-P MagiorakosD L Monnet
Jul 3, 2015·Pharmacotherapy·Jonathan C ChoSandy J Estrada
Jul 15, 2015·The Annals of Pharmacotherapy·Allana J SucherMatthew Fete
Nov 20, 2015·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Michael A NowakMark A Beilke
Feb 13, 2016·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Elizabeth CerceoAlpesh N Amin
May 27, 2016·Microbiology Spectrum·Jose M Munita, Cesar A Arias
May 29, 2016·The Medical Clinics of North America·Andrew W HahnDavid H Spach
Mar 23, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jose M MunitaCesar A Arias
May 13, 2017·Journal of Global Antimicrobial Resistance·Nadia CastaldoMatteo Bassetti

❮ Previous
Next ❯

Citations

Jul 18, 2019·Therapeutic Advances in Drug Safety·Xing Tan, Ryan P Moenster
Apr 10, 2021·Antimicrobial Resistance and Infection Control·Laura PuzniakAshley Enstone

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.